Full Text View
Tabular View
No Study Results Posted
Related Studies
A Comparison of Sertraline-Reboxetine Combination Therapy Versus Sertraline or Reboxetine Monotherapy in the Treatment of Major Depression.
This study has been completed.
Study NCT00636246   Information provided by Pfizer
First Received: March 7, 2008   Last Updated: April 3, 2008   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Depressive Disorder, Major
Additional conditions recognized in this trial
Depression
Depressive Disorder
Disease
More general conditions related to this trial
Behavioral Symptoms
Mental Disorders
Mood Disorders
Pathologic Processes
Interventions listed in this trial
sertraline/[S,S]-reboxetine
sertraline
Placebo
[S,S]-reboxetine monotherapy
Additional drug interventions recognized in this trial
Reboxetine
More general drug interventions related to this trial
Adrenergic Agents
Adrenergic Uptake Inhibitors
Antidepressive Agents
Central Nervous System Agents
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Neurotransmitter Uptake Inhibitors
Pharmacologic Actions
Physiological Effects of Drugs
Psychotropic Drugs
Serotonin Agents
Serotonin Uptake Inhibitors
Therapeutic Uses
Sponsors listed in this trial
Pfizer


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services